
Release date: 2025-03-10 10:36:16 Article From: Lucius Laos Recommended: 243
The development of cancer treatment drugs has brought hope to patients, but it has also been accompanied by concerns about the side effects of drugs. This article will discuss the use of osimertinib, a lung cancer treatment, and its possible side effects.
In the treatment of lung cancer, osimertinib has been widely recognized as the first-line standard of care for patients with advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations. However, any drug has the potential to bring side effects, and osimertinib is no exception.
According to clinical data, one of the most common adverse reactions of osimertinib is diarrhea, which was reported in about 31.4% of patients. In addition to this, skin problems and paronychia may also experience side effects associated with EGFR inhibitors. These side effects, while not always severe, do affect the quality of life of a subset of patients.
In addition to side effects, another concern for osimertinib is its resistance. Approximately 43.8% of patients developed brain or meningeal metastases after treatment with osimertinib. This means that over time, some patients may find that the drug is less effective and need to consider other treatment options.
For those who experience osimertinib resistance, doctors often recommend anti-angiogenic drugs as part of subsequent treatment. In addition, specific genetic variants, such as the C797S mutation, may require a more individualized treatment strategy.
As medical research advances, scientists are looking for more effective treatments with fewer side effects to fight cancer.
To overcome the limitations of existing drugs, researchers are working on the development of novel targeted drugs. For example, fruquintinib was included in the NCCN guidelines for its high-level evidence-based evidence, marking a substantial advance in the treatment of colorectal cancer. These new drugs not only improve the efficacy, but also have the potential to reduce the strong side effects of traditional chemotherapy.
Personalized medicine has become an important trend in oncology. Through genetic testing and other diagnostic tools, doctors are able to better understand the characteristics of each patient's disease and develop a treatment plan that works best for them. This includes choosing the most appropriate combination of medications as well as adjusting the dosage to achieve the best results while minimizing side effects.
Despite significant advances in targeted therapy, monotherapy is often difficult to cure complex diseases. A comprehensive treatment strategy that combines surgery, radiotherapy, chemotherapy and other means is particularly important. Such multidisciplinary collaboration can help improve patient survival and improve quality of life.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3502025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3512025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3932025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3262025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3012025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643